This study is in progress, not accepting new patients
A Study Evaluating AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Solid Tumors
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at UCLA UCSD UCSF
- Dates
- study startedstudy ends around
- Principal Investigator
- by Alain Algazi (ucsf)
Description
Summary
Official Title
Keywords
Eligibility
Locations
Lead Scientist at University of California Health
- Alain Algazi (ucsf)
Dr. Alain Algazi is a specialist in medical treatment – such as chemotherapy and immunotherapy – for patients with head and neck cancers, including head and neck squamous cell carcinoma, thyroid cancers and salivary gland cancers. He leads UCSF's program in medical therapy for head and neck cancers, and chairs the head and neck cancer research committee.
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Asher Biotherapeutics, Inc.
- ID
- NCT05653882
- Phase
- Phase 1 research study
- Study Type
- Interventional
- Participants
- Expecting 552 study participants
- Last Updated